| 摘要 |
FIELD: medicine, oncology. ^ SUBSTANCE: group of inventions relates to medicine in particular to oncology and can be used for treatment of cancer or precancer conditions associated with CD40-expressing cells of the patient, heterozygous or homozygous concerning FcRIIIa-158F (genotype V/F or F/F); the invented medications include variants of the monoclonal antibodies to CD40 which bind with the epitope which can bind with the monoclonal antibody CHIR-12.12; the invented methods include the identification of a human patient suffering from cancer or precancer conditions to be cured by the antibody to CD40 which are resistant to treatment by rituximab, by means of the determination of the genotype FcRIIIa-158F (genotype V/V, V/F or F/F) with application of the biological specimen attained from this human patient. ^ EFFECT: application of the method allows to cure cancer or precancer conditions resistant to rituximab. ^ 43 cl, 1 tbl, 14 dwg, 7 ex |
